Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
10 Health Care Stocks With Whale Alerts In Today's Session
Behind the Scenes of Merck & Co's Latest Options Trends
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.
Intuitive Surgical's Options: A Look at What the Big Money Is Thinking
Edwards Lifesciences Downgraded at Jefferies on Lower TAVR Growth
Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Eli Lilly
BioNTech Raised to Buy at Jefferies on New Cancer Drug
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Insulet Analyst Ratings
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC